Article and Video CATEGORIES

Cancer Journey

Search By

Is the Survival Benefit with Avastin Added to Chemotherapy Enough to Change the Standard of Care in Mesothelioma?
Author
GRACE Videos and Articles

WCLC_2015_Avastin_Chemotherapy_Mesothelioma_Survival_Benefit_Enough

 

Drs. Ben Solomon, Leora Horn, & Jack West discuss highlights of a French randomized trial that demonstrated a significant survival benefit from addition of Avastin (bevacizumab) to cisplatin/Alimta in patients with malignant pleural mesothelioma.

[powerpress]

Download Transcript

[ratingwidget post_id=0]

Please feel free to offer comments and raise questions in our Discussion Forums.

 

Transcript

Dr. West:  So, one of the other topics that’s covered in this broad thoracic malignancies conference is mesothelioma, where one of the biggest bits of news that we got this year actually came at ASCO, earlier this year, in a French trial that showed that adding Avastin (bevacizumab) to standard chemotherapy, in this case, cisplatin and Alimta (pemetrexed), seemed to improve survival in a clinically significant way. What do you think of these data — is this changing practice for you or around you, Ben?

Dr. Solomon:  Sure, look, I think it’s an important study — the initial study that showed benefit of cisplatin and pemetrexed, over cisplatin alone, was the first phase three study that showed a survival benefit in mesothelioma. This is the second study, and I think the benefits are meaningful. There was an improvement in progression-free survival of about two months — the improvement in overall survival was a bit more than that. So, I do think that that difference is meaningful, and I think it’s likely that bevacizumab, in that context, will get incorporated into standard practice.

Dr. West:  What do you say?

Dr. Horn:  I think that is possible — what I worry is that pemetrexed and bevacizumab together is a more toxic combination, and it is not as easy and as tolerable as pemetrexed alone, but for those patients who can tolerate it, it is a good, new treatment option for them.

Dr. West:  So it’s not something you’re uniformly inclined to incorporate for most or all of your patients with mesothelioma?

Dr. Horn:  It’s such a rare disease, so not right now. What I also worry about is a lot of the mesothelioma patients are older, and, so, that same worry about tolerability.

Next Previous link

Previous PostNext Post

Related Content

Article
The journey to conquer lung cancer is paved with scientific discovery, and the identification of the EGFR and ALK genes as crucial players marks a significant milestone. Unraveling how mutations in these seemingly small segments of our DNA can unleash the destructive force of cancer has opened up exciting new therapeutic avenues. This exploration delves into the cutting-edge world of EGFR and ALK-targeted therapies, highlighting the progress made and the ongoing quest for even more effective and personalized strategies to combat this formidable disease.
Image
Rare cancers
Video
In these videos,  Dr. Jared Weiss gives a brief overview of NUT Carcinoma, discusses treatment options and possible future treatment.  To watch the complete playlist, click here.  
Article
Don't let the word "small" deceive you. Small cell lung cancer (SCLC) casts a long shadow, impacting lives with its aggressive nature and the complexities of its treatment. But while the challenges are real, so is the progress. Breakthroughs in small cell lung cancer treatment offer hope. Immunotherapy plus chemo-radiation improves survival by 22 months. Screening catches it early.

Forum Discussions

Can SCLC also be treated with targeted therapy?

Hi amitchouhan,

Welcome to Grace. At this time, there aren't any targeted therapies to treat SCLC, but there are new treatments. Check out our latest OncTalk webinar from December. The last...

I was searching for this, Thank you so much for the info.

Recent Comments

JOIN THE CONVERSATION
Yes, it's crucial to discuss…
By JanineT GRACE … on
Definitely a good idea to…
By OakleeFarnick on
Thank you for sharing
By LeviDrake on